Recognition and management of gliomas

Drugs

Volumn 53, Issue 2, 1997, Pages 235-244

  Kaba, Samer E ^a,c   Kyritsis, Athanassios P ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ARYLBUTYRIC ACID DERIVATIVE; BETA INTERFERON; CARBOPLATIN; CARMUSTINE; CORTICOSTEROID; ETOPOSIDE; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GADOLINIUM; HYDROXYUREA; ISOTRETINOIN; LOMUSTINE; MONOCLONAL ANTIBODY; PHENYLACETIC ACID; PROCARBAZINE; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; TIOGUANINE; TOPOTECAN; VINCRISTINE;

ASTROCYTOMA; BRAIN BIOPSY; BRAIN STEM TUMOR; BRAIN SURGERY; BRAIN TUMOR; CANCER INFILTRATION; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; EPENDYMOMA; GLIOMA; HEADACHE; HEMIPARESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MENTAL DISEASE; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; ORAL DRUG ADMINISTRATION; PROGNOSIS; REVIEW; SEIZURE; SYMPTOM;

EID: 0031015591     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199753020-00004     Document Type: Review

References (56)

1. CBTRUS First Annual Report. Central Brain Tumor Registry of the United States. Chicago: 1995
2. Desmeules M, Mikkelsen T, Mao Y. Increasing incidence of primary malignant brain tumors: influence of diagnostic methods. J Natl Cancer Inst 1992; 84: 442-5
3. Trouillas P, Menaud G, De The G, et al. Étude épidémiologique des tumeurs primitives du neuraxe dans la région Rhône-Alpes. Rev Neurol 1975; 131: 691-708
4. Kyritsis AP, Saya H. Epidemiology, cytogenetics, and molecular biology of brain tumors. Curr Opin Oncol 1993; 5: 474-80
5. Pell MF, Thomas DGT. General introduction to clinical features of malignant brain tumours. In: Thomas DGT, Graham DI, editors. Malignant brain tumours. London: Springer-Verlag, 1995: 109-14
6. Nelson JS, Tsukada Y, Schoenfeld D, et al. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 1983; 52: 550
7. Burger PC, Vogel FS, Green SB, et al. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 1985; 56: 1106-11
8. Russell DS, Rubenstein LJ. Pathology of tumors of the nervous system. 5th ed. London: Edward Arnold, 1989
9. Muller W, Afra D, Schroder R. Supratentorial recurrences of gliomas: morphological studies in relation to time intervals with astrocytomas. Acta Neurorchir 1977; 37: 75-91
10. Burger PC, Shibata T, Kleihues P. The use of monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol 1986; 10: 611-7
11. Labrousse F, Daumas-Duport C, Batorski L, et al. Histological grading and bromodeoxyuridine labeling index of astrocytomas. J Neurosurg 1991; 75: 202-5
12. Brown MT, Friedman HS, Oakes WJ. Chemotherapy of pilocytic astrocytomas. Cancer 1993; 71: 3165-72
13. Levin VA, Gutin PH, Leibel SA. Neoplasms of the central nervous system. In: DeVita VTJ, Hellman S, Rosenberg JB, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott, 1993: 1679-737
14. Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Ann Neurol 1992; 31: 431-6
15. Chamberlain MC, Murovic JA, Levin VA. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology 1988; 38: 1371-4
16. Shaw EG, Scheithauer BW, Gilbertson DT, et al. Postoperative radiotherapy of supratentorial low-grade gliomas. Int J Radiat Oncol Biol Phys 1989; 16: 663-8
17. Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg 1993; 78: 909-14
18. Wood JR, Greene SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 1988; 6: 338-43
19. Walker MD. Adjuvant therapy for brain tumor. Int Adv Surg Oncol 1980; 3: 351-69
20. Walker MD, Alexander EJ, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 1978; 49: 333-43
21. Leibel SA, Sheline GE. Radiation therapy for neoplasms of the brain. J Neurosurg 1987; 66: 1
22. Shin KH, Muller PJ, Geggie PH. Superfractionation radiation therapy in the treatment of malignant astrocytoma. Cancer 1983; 52: 2040-3
23. Urtasun RC, Feldstein ML, Partington J, et al. Radiation therapy and nitroimidazoles in supratentorial high grade gliomas: a second clinical trial. Br J Cancer 1982; 46: 101-8
24. Loeffler JS, Alexander III E, Wen PY, et al. Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J Natl Cancer Inst 1990; 82: 1918-21
25. Florell RC, Macdonald DR, Irish WD, et al. Selection bias, survival, and brachytherapy for glioma. J Neurosurg 1992; 76: 179-83
26. Loeffler JS, Alexander III E, Shea WM, et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 1992; 10: 1379-85
27. Levin VA, Freeman-Dove MA, Landahl H. Permeability characteristics of brain adjacent to tumors in rats. Arch Neurol 1975; 32: 785-91
28. Walker MD, Alexander Jr E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg 1978; 49: 333-43
29. Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71: 2585-97
30. Kyritsis AP. Chemotherapy for malignant gliomas. Oncology 1993; 7: 93-100
31. Conrad CA, Milosavljevic VP, Yung WK. Advances in chemotherapy for brain tumors. Neurol Clin 1995; 13: 795-812
32. Levin VA, Silver P, Hannigan J, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G6I final report. Int Radiat Oncol Biol Phys 1990; 18: 321-4
33. Banerjee AK, Sharma BS, Kak VK, et al. Gliosarcoma with cartilage formation. Cancer 1989; 63: 518-23
34. Boiardi A, Silvani A, Milanesi I, et al. Primary glial tumor patients treated by combining cis-platin and etoposide. J Neurooncol 1991; 11: 165-70
35. Yung WK, Janus TJ, Maor M, et al. Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. J Neurooncol 1992; 12: 131-5
36. Shapiro WR, Green SB, Burger PC, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992; 76: 772-81
37. Lesser GJ, Grossman S. The chemotherapy of high grade astrocytomas. Semin Oncol 1994; 21: 220-35
38. Berger MS, Tucker A, Spence A, et al. Reoperation for glioma. Clin Neurosurg 1992; 39: 172-86
39. Sneed PK, Gutin PH, Prados MD, et al. Brachytherapy of brain tumors. Stereotact Funct Neurosurg 1992; 59: 157-65
40. Coyle T, Baptista J, Winfield J, et al. Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. J Clin Oncol 1990; 8: 2014-8
41. Buckner JC, Brown LD, Cascino TL, et al. Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma. J Neurooncol 1990; 9: 244-54
42. Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant gliomas: a phase II study. J Clin Oncol 1991; 9: 860-4
43. Poisson M, Pereon Y, Chiras J, et al. Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J Neurooncol 1991; 10: 139-44
44. Rodriguez LA, Prados M, Silver P, et al. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 1989; 64: 2420-3
45. Newton HB, Junck L, Bromberg J, et al. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Cancer 1990; 40: 1743-6
46. Kyritsis AP, Yung WK, Jaeckle KA, et al. Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. Neurosurgery 1996; 39: 921-6
47. Yung WK, Prados M, Levin VA, et al. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol 1991; 9: 1945-9
48. Couldwell WT, Weiss MH, DeGiorgio CM, et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993; 32: 485-9
49. Ram Z, Culver KW, Walbridge S, et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancel Res 1993; 53: 83-8
50. Kyritsis AP, Yung WK, Bruner J, et al. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 1993; 32: 365-70
51. Cairncross G, McDonald D, Ludwin S. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994; 12: 2013-21
52. Jay V, Squire J, Becker L, et al. Malignant transformation in a ganglioglioma with anaplastic neuronal and astrocytic components. Cancer 1994; 73: 2862-8
53. Kaba SE, Langford LA, Yung WK, et al. Resolution of recurrent malignant ganglioglioma after treatment with cis-retinoic acid. J Neurooncol 1996; 30: 55-60
54. Vanuytsel L, Brada M. The role of prophylactic spinal irradiation in localized intracranial ependymoma. Int J Radiat Oncol Biol Phys 1991; 21: 825-30
55. Kovalic JJ, Flaris N, Grigsby PW, et al. Intracranial ependymoma long-term outcome, patterns of failures. J Neurooncol 1983; 15: 125-31
56. Maria BL, Rehder K, Eskin TA, et al. Brainstem glioma: I. Pathology, clinical features, and therapy. J Child Neurol 1993; 8: 112-28